Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis

Annals of Internal Medicine

Volumn 127, Issue 12, 1997, Pages 1051-1061

  Salpeter, Shelley R ^a   Sanders, Gillian D ^b   Salpeter, Edwin E ^c   Owens, Douglas K ^d  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cornell University ^*  (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; HEPATITIS; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; PROBABILITY; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 0031435832     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-12-199712150-00001     Document Type: Article

References (97)

1. Barnes PF, Barrows SA. Tuberculosis in the 1990s. Ann Intern Med. 1993; 119:400-10.
2. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Advances in Tuberculosis Research. 1970;17:28-106.
3. Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis. 1963;88:161-75.
4. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967;95:935-43.
5. Hanson ML, Comstock GW, Haley CE. Community isoniazid prophylaxis program in an underdeveloped area of Alaska. Public Health Rep. 1967;82:1045-56.
6. Houk VN, Kent DC, Sorensen K, Baker JH. The eradication of tuberculosis infection by isoniazid chemoprophylaxis. Arch Environ Health. 1968;16:46-50.
7. Grzybowski S, Ashley MJ, McKinnon NE, Pinkus G, Philipps R, Brown A. In Canada: a trial of chemoprophylaxis in inactive tuberculosis. Can Med Assoc J. 1969;101:555-60.
8. Hsu KH. Isoniazid in the prevention and treatment of tuberculosis. A 20-year study of the effectiveness in children. JAMA. 1974;229:528-33.
9. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. Isoniazid-assodated hepatitis. Report of an outbreak. Am Rev Respir Dis. 1972;106:357-65.
10. Kuller LH, Perper JA, Cooper M, Fisher R. An epidemic of deaths attributed to fatty liver in Baltimore. Prev Med. 1974;3:61-79.
11. Levin ML, Moodie AS. Isoniazid prophylaxis and deaths in Baltimore, 1972. Md Med J. 1974;23:64-7.
12. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978; 117:991-1001.
13. Dash LA, Comstock GW, Flynn JP. Isoniazid preventive therapy: retrospect and prospect. Am Rev Respir Dis. 1980;131:1039-44.
14. Preventive therapy of tuberculous infection. Am Rev Respir Dis. 1974; 110: 371-4.
15. Treatment of tuberculosis and other mycobacterial diseases. Am Rev Respir Dis. 1983;127:790-6.
16. Bailey WC, Byrd RB, Glassroth JL, Hopewell PC, Reichman LB. Preventive treatment of tuberculosis. Chest. 1985;87(2 Suppl):128S-32S.
17. Taylor WC, Aronson MD, Delbanco TL. Should young adults with a positive tuberculin test take isoniazid? Ann Intern Med. 1981;94:808-13.
18. Rose DN, Schechter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors. JAMA. 1986; 256:2709-30.
19. Cooper JK. Decision analysis for tuberculosis preventive treatment in nursing homes. J Am Geriatr Soc. 1986;34:814-7.
20. Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis. 1988;137:215-20.
21. Jordan TJ. Isoniazid preventive therapy for low-risk tuberculin reactors. Bull Int Union Tuberc Lung Dis. 1990-91;66(Suppl):21-2.
22. Jordan TJ, Lewitt EM, Reichman LB. Isoniazid preventive therapy for tuberculosis. Decision analysis considering ethnicity and gender. Am Rev Respir Dis. 1991;144:1357-60.
23. Colice GL. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch Intern Med. 1990;150: 2517-22.
24. Dolan JG, Bordley DR. Isoniazid prophylaxis: the importance of individual values. Med Decis Making. 1994;14:1-8.
25. Sterling TR, Brehm WT, Frieden TR. Isoniazid preventive therapy in areas of high isoniazid resistance. Arch Intern Med. 1995;155:1622-8.
26. Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med. 1973;79: 1-12.
27. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology. 1975;69:289-302.
28. Byrd RB, Horn BR, Solomon DA, Griggs GA. Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. JAMA. 1979;241:1239-41.
29. Comstock GW. Evaluating isoniazid preventive therapy: the need for more data [Editorial]. Ann Intern Med. 1981;94:817-9.
30. Grzybowski S, Ashley MJ, Pinkus G. Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial. Can Med Assoc J. 1976;114: 607-11.
31. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982; 60:555-64.
32. Nolan CM, Aitken ML, Elarth AM, Anderson KM, Miller WT. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am Rev Respir Dis. 1986;133:431-6.
33. Franks AL, Binkin NJ, Snider DE Jr, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep. 1989;104:151-5.
34. Vadasz I. [Adverse reactions to isoniazid.] Bull Int Union Tuberc. 1974;49: 294-300.
35. Thompson JE. How safe is isoniazid? Med J Aust. 1978;1:165-9.
36. Salpeter SR. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med. 1993;159:560-4.
37. Millard PS, Wilcosky TC, Reade-Christopher SJ, Weber DJ. Isoniazid-related fatal hepatitis. West J Med. 1996;164:486-91.
38. Stead WW, To T, Harrison RW, Abraham JH 3d. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med. 1987;107:843-5.
39. Comstock GW. Frost revisited: the modern epidemiology of tuberculosis. Am J Epidemiol. 1975;101:363-82.
40. Centers for Disease Control and Prevention. Tuberculosis in the United States. Atlanta, GA: Centers for Disease Control and Prevention; 1991:14-79.
41. Centers for Disease Control and Prevention. Tuberculosis in the United States. Atlanta, GA: Centers for Disease Control and Prevention; 1992:67.
42. Salpeter EE, Salpeter SR. A mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. Am J Epidemiol. [In press].
43. National Center for Health Statistics. Monthly Vital Statistics Report: Annual Summary of Births, Marriages, Divorces, and Deaths: United States, 1994. Washington, DC: U.S. Public Health Service; 1995.
44. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996:214-46.
45. Brown RE, Miller B, Taylor WR, Palmer C, Bosco L, Nicola RM, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med. 1995;155:1595-600.
46. Physicians' Current Procedural Terminology (CPT) 1996. Chicago: American Med Assoc; 1995.
47. Medicare RBRVS: The Physicians' Guide. Chicago: American Med Assoc; 1996.
48. Medicode. Fee and Coding Standard. 2d ed. Salt Lake City, UT: Medicode; 1997.
49. Health Care Investment Analysts, Inc. The Medicare DRG Handbook. Baltimore, MD: Ernst & Young; 1996.
50. Mohle-Boetani JC, Miller B, Halpern M, Trivedi A, Lessler J, Solomon SL, et al. School-based screening for tuberculous infection. A cost-benefit analysis. JAMA. 1995;274:613-9.
51. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-58.
52. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
53. Comstock GW, Woolpert SF, Livesay VT. Tuberculosis studies in Muscogee County, Georgia. Twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep. 1976;91:276-80.
54. Horwitz O, Wilbek E, Erickson PA. Epidemiological basis of tuberculosis eradication. 10. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull World Health Organ. 1969;41:95-113.
55. Comstock GW, Woolpert SF, Baum C. Isoniazid prophylaxis among Alaskan Eskimos: a progress report. Am Rev Respir Dis. 1974;110:195-7.
56. Burrill D, Enarson DA, Allen EA, Grzybowski S. Tuberculosis in female nurses in British Columbia: implications for control programs. Can Med Assoc J. 1985;132:137-40.
57. Mackay AD, Cole RB. The problems of tuberculosis in the elderly. Q J Med. 1984;53:497-510.
58. Cullinan P, Meredith SK. Deaths in adults with notified pulmonary tuberculosis 1983-5. Thorax. 1991;46:347-50.
59. Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med. 1969;71:1113-20.
60. Byrd CB, Nelson R, Elliott RC. Isoniazid toxicity. A prospective study in secondary chemoprophylaxis. JAMA. 1972;220:1471-3.
61. Bailey WC, Taylor SL, Dascomb HE, Greenberg HB, Ziskind MM. Disturbed hepatic function during isoniazid chemoprophylaxis. Monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis. Am Rev Respir Dis. 1973;107:523-9.
62. Beaudry PH, Brickman HF, Wise MB, MacDougall D. Liver enzyme disturbances during isoniazid chemoprophylaxis in children. Am Rev Respir Dis. 1974;110:581-4.
63. Bailey WC, Weill H, DeRouen TA, Ziskind MM, Jackson HA, Greenberg HB. The effect of isoniazid on transaminase levels. Ann Intern Med. 1974;81: 200-2.
64. Mitchell JR, Long MW, Thorgeirsson UP, Jollow DJ. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest. 1975;68:181-90.
65. Litt IF, Cohen MI, McNamara H. Isoniazid hepatitis in adolescents. J Pediatr. 1976;89:133-5.
66. Rapp RS, Campbell RW, Howell JC, Kendig EL Jr. Isoniazid hepatotoxicity in children. Am Rev Respir Dis. 1978;118:794-6.
67. Thomas PA Jr, Mozes MF, Jonasson O. Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients. Arch Surg. 1979;114: 597-9.
68. Spyridis P, Sinaniotis C, Papadea I, Oreopoulos L, Hadjiyiannis S, Papadatos C. Isoniazid liver injury during chemoprophylaxis in children. Arch Dis Child. 1979;54:65-7.
69. Adverse drug reactions among children treated for tuberculosis. MMWR Morb Mortal Wkly Rep. 1980;29:589-91.
70. Dickinson DS, Bailey WC, Hirschowitz BI, Soong SJ, Eidus L, Hodgkin MM. Risk factors for isoniazid (INH)-induced liver dysfunction. J Clin Gastroenterol. 1981;3:271-9.
71. Mehta JB, Dutt AK, Harvill L, Henry W. Isoniazid preventive therapy for tuberculosis. Are we losing our enthusiasm? Chest. 1988;94:138-41.
72. Nakajo MM, Rao M, Steiner P. Incidence of hepatotoxicity in children receiving isoniazid chemoprophylaxis. Pediatr Infect Dis J. 1989;8:649-50.
73. Alcabes P, Vossenas P, Cohen R, Braslow C, Michaels D, Zoloth S. Compliance with isoniazid prophylaxis in jail. Am Rev Respir Dis. 1989;140: 1194-7.
74. Quillan S, Malotte CK, Shlian D. Evaluation of a tuberculosis screening and prophylaxis program for international students. J Am Coll Health. 1990;38: 165-70.
75. Nazar V, Oberle M, Nolan C. Results of a directly-observed, intermittent isoniazid preventive therapy program in a shelter for homeless men [Abstract]. Am Rev Respir Dis. 1990;141S:A438.
76. Wadhawan D, Hira S, Mwansa N, Tembo G, Perine P. Isoniazid prophylaxis among patients with HIV-1 infection [Abstract]. Proceedings and Abstracts of the Sixth International Conference on AIDS, San Francisco, 20-24 June 1990. San Francisco: Univ of California; 1990;1:A249.
77. Geiter L, O'Brian R, Kopanoff D. Short-course preventive therapy for tuberculosis [Abstract]. Am Rev Respir Dis. 1990;141S:A437.
78. Rabindran E, Matuszak DL, Israel E, Woodall H, Highsmith H, Flynn J. Preventive therapy for tuberculosis in Maryland. Md Med J. 1991;40:793-7.
79. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis. 1992;145:36-41.
80. Gurumurthy P, Krishnamurthy MS, Nazareth O, Parthasarathy R, Sarma GR, Somasundaram PR, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis. 1984; 129:58-61.
81. Fitzgerald JM, Allen EA, Elwood RK, Chao CW. Isoniazid chemoprophylaxis in British Columbia 1982-1987 [Abstract]. Am Rev Respir Dis. 1990;141S: A438.
82. Fitzgerald JM, Gafni A. A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test. Am Rev Respir Dis. 1990;142:848-53.
83. Economic Report of the President. Washington, DC: U.S. Gov Pr Office; 1997.
84. Trump DH, Hyams KC, Cross ER, Struewing JP. Tuberculosis infection among young adults entering the US Navy in 1990. Arch Intern Med. 1993; 153:211-6.
85. Blum RN, Polish LB, Tapy JM, Catlin BJ, Cohn DL. Results of screening for tuberculosis in foreign-born persons. Chest. 1993;103:1670-4.
86. Rosenberg T, Manfreda J, Hershfield ES. Two-step tuberculin testing in staff and residents of a nursing home. Am Rev Respir Dis. 1993;148:1537-40.
87. Bailey TC, Fraser VJ, Spitznagel EL, Dunagan WC. Risk factors for a positive tuberculin skin test among employees of an urban, midwestern teaching hospital. Ann Intern Med. 1995;122:580-5.
88. Centers For Disease Control and Prevention. Core Curriculum on Tuberculosis. Atlanta, GA: Centers for Disease Control and Prevention; 1994:13.
89. Reported Tuberculosis in the United States 1995. Atlanta, GA: Centers for Disease Control and Prevention; 1996:5-12.
90. National Center for Health Statistics. Vital Statistics of the U.S. 1988. Volume II, Mortality, Part A. Washington, DC: U.S. Public Health Service; 1991.
91. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin therapy on quality of life. Arch Intern Med. 1996;156:1829-36.
92. Screening for tuberculosis and tuberculous infection in high-risk populations. MMWR Morb Mortal Wkly Rep. 1990;39:1-12.
93. Barnes PF, Bloch AB, Davidson PT, Snider DE Jr. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1991;324:1644-50.
94. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society. Am Rev Respir Dis. 1986;134:355-63.
95. Salpeter S. Tuberculosis chemoprophylaxis. West J Med. 1992;157:421-4.
96. Glassroth J, Bailey WC, Hopewell PC, Schecter G, Harden JW. Why tuberculosis is not prevented. Am Rev Respir Dis. 1990;141(5 Pt 1):1236-40.
97. Mori MA, Leonardson G, Welty TK. The benefits of isoniazid chemoprophylaxis and risk factors for tuberculosis among Oglala Sioux Indians. Arch Intern Med. 1992;152:547-50.